Esperion Therapeutics has hired Benjamin Looker as general counsel to lead the company’s legal, compliance and ethics operations.
Looker most recently worked at Trillium Therapeutics, where he was the company’s first general counsel and handled all legal matters, including corporate governance and SEC compliance, risk management and intellectual property asset protection, until the company’s acquisition by Pfizer in November 2021.
Before his time at Trillium Therapeutics, Looker was vice president and head of US legal and global business operations for MorphoSys US, a commercial-stage biopharmaceutical company, where he advised on business initiatives such as sales and marketing activities, business development, corporate structure, the enforcement environment and risk mitigation strategies.
Prior to MorphoSys, he held legal roles at EMD Serono, a US subsidiary of Darmstadt, Germany-based Merck. Looker began his legal career as a corporate attorney at Goodwin Procter.
Sheldon Koenig, president and CEO of Esperion, says in a statement: ‘Mr Looker is a highly experienced legal executive with broad pharmaceutical industry experience, and proven skill supporting clinical and commercial-stage companies, and I welcome him to Esperion.’
Looker says in the announcement: ‘I am thrilled to join the team at Esperion, particularly at such an exciting time as we anticipate the completion of the cardiovascular outcomes trial and determine future steps for the company’s early stage pipeline, which has potential to impact millions of patients.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
